Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)

Hamdy A Azim,1 Ashraf Omar,2 Hesham Atef,1,&dagger; Heba Zawahry,3 Mohamed K Shaker,4 AH Kamel Abdelmaksoud,5 Mohamed EzzElarab,6 Omar Abdel-Rahman,7 Mohamed Ismail,8 Loay Kassem,1 Imam Waked9 1Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of G...

Full description

Bibliographic Details
Main Authors:	Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AHK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	Journal of Hepatocellular Carcinoma
Subjects:	Advanced hepatocellular carcinoma sorafenib Tegafur/uracil Egypt
Online Access:	https://www.dovepress.com/sorafenib-plus-tegafur-uracil-uft-versus-sorafenib-as-first-line-syste-peer-reviewed-article-JHC

Similar Items

Using oral tegafur/uracil (UFT) plus leucovorin as adjuvant chemotherapy in stage II colorectal cancer: a propensity score matching study from Taiwan
by: Yen-Lin Yu, et al.
Published: (2023-09-01)

The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience
by: Tsung-Jang Yeh, et al.
Published: (2021-02-01)

Benefit of Uracil–Tegafur Used as a Postoperative Adjuvant Chemotherapy for Stage IIA Colon Cancer
by: Po-Huang Chen, et al.
Published: (2022-12-01)

Platinum Plus Tegafur–Uracil versus Platinum Alone during Concurrent Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma: A Propensity-Score-Matching Analysis
by: Ching-Feng Lien, et al.
Published: (2022-09-01)

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
by: Sheng‐Kai Liang, et al.
Published: (2023-09-01)

Maintenance tegafur-uracil versus observation following an adjuvant oxaliplatin-based regimen in patients with stage III colon cancer after radical resection: study protocol for a randomized controlled trial
by: Yung-Sung Yeh, et al.
Published: (2017-04-01)

Adjuvant tegafur-uracil (UFT) or S-1 monotherapy for advanced gastric cancer: a single center experience
by: Hung-Hsuan Yen, et al.
Published: (2021-04-01)

Tegafur‐uracil‐induced pericardial effusion during adjuvant chemotherapy for resected lung adenocarcinoma: A case report
by: Nobutaka Kawamoto, et al.
Published: (2021-03-01)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
by: Satya Pal Kataria, et al.
Published: (2022-01-01)

Cisplatin, tegafur-uracil and leucovorin plus mitomycin C: an acceptably effective and toxic regimen for patients with recurrent or metastatic nasopharyngeal carcinoma
by: Chia-Hsun Hsieh, et al.
Published: (2013-10-01)

Maintenance tegafur-plus-uracil after adjuvant concurrent chemoradiotherapy may improve outcome for resected oral cavity squamous cell carcinoma with extranodal extension
by: Pei-Wei Huang, et al.
Published: (2022-09-01)

Complete Response of Pulmonary Metastases from Rectal Cancer to Tegafur-Uracil/Leucovorin plus Bevacizumab in an Elderly Patient: A Case Report
by: Masatsune Shibutani, et al.
Published: (2018-07-01)

Monthly tegafur–uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study
by: Yi-Hung Kuo, et al.
Published: (2019-08-01)

Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
by: Meng-Che Hsieh, et al.
Published: (2021-10-01)

Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy
by: Takehito Shukuya, MD, PhD, et al.
Published: (2022-05-01)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
by: Fumiya Sugino, et al.
Published: (2023-04-01)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023-06-01)

A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study
by: Tomoshi Tsuchiya, et al.
Published: (2020-12-01)

Tegafur-induced acral hyperpigmentation
by: Vera Teixeira, et al.
Published: (2011-09-01)

A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis
by: Sun Young Kim, et al.
Published: (2017-03-01)

Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer
by: Takanori Goi, et al.
Published: (2011-02-01)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
by: Oronzo Brunetti, et al.
Published: (2019-10-01)

A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)Central MessagePerspective
by: Hideo Kunitoh, MD, et al.
Published: (2020-12-01)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
by: Fornari F, et al.
Published: (2021-07-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
by: Hong-Yue Lai, et al.
Published: (2021-01-01)

Sorafenib-induced acute pancreatitis
by: Han-En Wang, et al.
Published: (2014-01-01)

Predictive value of platelet-to-lymphocyte and neutrophil-to-lymphocyte ratio in HCC treated with sorafenib and radioembolization
by: Osman Öcal, et al.
Published: (2024-04-01)

β-HB treatment reverses sorafenib resistance by shifting glycolysis–lactate metabolism in HCC
by: Fat-Moon Suk, et al.
Published: (2023-10-01)

Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
by: Ritu Shrestha, et al.
Published: (2021-06-01)

Concurrent chemoradiotherapy using cisplatin, tegafur, and leucovorin for advanced squamous cell carcinoma of the hypopharynx and oropharynx
by: Hung-Ming Wang, et al.
Published: (2014-06-01)

Computational study of uracil tautomeric forms in the ribosome : the case of uracil and 5-oxyacetic acid uracil in the first anticodon position of tRNA
by: Hartono, Yossa Dwi, et al.
Published: (2019)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021-04-01)

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
by: Jialiang Luo, et al.
Published: (2022-10-01)

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
by: Max Seidensticker, et al.
Published: (2023-05-01)

A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
by: Jaejun Lee, et al.
Published: (2020-12-01)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
by: Xi He, et al.
Published: (2021-07-01)

Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
by: Bruno Sangro, et al.
Published: (2012-06-01)

Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
by: Agnieszka Karbownik, et al.
Published: (2021-12-01)